Efficacy of Tildrakizumab in Difficult-to-treat Areas in Psoriasis

N/AActive Not RecruitingNCT05938361

Clin4all120 enrolled

Overview

Psoriasis is a chronic inflammatory disease that affects between 2% and 4% of the French population.Some specific localizations are more difficult to manage, such as the scalp, nails, genital region and palmoplantar localizations. Tildrakizumab, an anti-interleukin-23 (IL-23) monoclonal antibody, has demonstrated efficacy and safety in the treatment of patients with moderate to severe psoriasis. Real-life data on the efficacy of Tildrakizumab in unselected patients with these difficult-to-treat locations are still limited. The aim of the ZODIPSO study is to evaluate the efficacy and safety of Tildrakizumab in patients presented difficult to treat locations in psoriasis : nail, scalp, genital and palmoplantar. The main objective is to assess the overall response and the specific response to Tildrakizumab at these specific areas up to W52.

Psoriasis is a chronic inflammatory disease that affects between 2% and 4% of the French population. Some specific localizations are more difficult to manage, such as the scalp, nails, genital region and palmoplantar localizations. They are reported at least once during the course of psoriatic disease in more than 80%, 50%, 60%, 12% of patients, respectively. Despite recent progress in the management of the disease, these localizations remain a challenge for psoriasis patients because of their impact on quality of life and the difficulty of treating them. Tildrakizumab, an anti-interleukin-23 (IL-23) monoclonal antibody, has already demonstrated efficacy and safety in the treatment of patients with moderate to severe psoriasis in two international multicenter randomized clinical trials : reSURFACE 1 and reSURFACE 2. However, real-life data on the efficacy of Tildrakizumab in unselected patients with these difficult-to-treat locations are still limited.

Study Type

OBSERVATIONAL

Enrollment

120

Conditions

Psoriasis Palmaris Psoriasis Genital

Interventions

Psoriasis clinical assessmentsOTHER

Global evaluation of psoriasis and specific evaluation by areas

Quality of life evaluationOTHER

DLQI questionnaire at each visit

Satisfaction assessmentOTHER

Visual analogic scale at W16, W28, W52

Pruritus evaluationOTHER

Visual analogic scale at each visit

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patient with a diagnosis of moderate to severe chronic plaque psoriasis documented in the medical record, 2. Disease diagnosis \> 6 months (regardless of severity at diagnosis) 3. Involvement of at least one of the following areas: nails, scalp, genital, palmoplantar (non-pustular) 4. Indication for treatment by IL-23 inhibitor. Tildrakizumab must be the selected IL-23 inhibitor therapy prior to enrolling the patient in the study. Patients who have previously received previous treatment by IL-23 inhibitors may be included. 5. Patient 18 years of age or older at the inclusion visit 6. French social security beneficiary Exclusion Criteria: 1. Patient unable to comply with study requirements (i.e.complete study questionnaires) 2. Patient who, in the opinion of the investigator, should not participate in the study. This opinion should be documented in the patient's record. 3. Patient included in an interventional clinical trial at inclusion. 4. Vulnerable patient or patient under court protection 5. Patients with known hypersensitivity to IL-23 inhibitors 6. Patients with HIV or active HBV or HCV infection at the time of inclusion 7. Patient with a history of untreated latent tuberculosis or active tuberculosis at inclusion 8. Patient with any other serious active infection present at inclusion that contraindicates IL23 inhibitors use. 9. Pregnant or lactating woman

Outcomes

Primary Outcomes

Specific response to Tildrakizumab at W28

Percentage of response based on specific assessment on target area (75% improvement of the specific score compared to Baseline visit)

Time frame: Week 28

Secondary Outcomes

Overall response to Tildrakizumab

Percentage of response based on global assessment compared to Baseline visit

Time frame: Each visit (Week16-Week 28-Week 52)

Specific response to Tildrakizumab

Percentage of response based on specific assessment by area compared to Baseline Visit

Time frame: Week 16, week 28 and week 52

Adverse events

Describe adverse events throughout follow-up

Time frame: From baseline visit to Week 52

Evaluation of pruritus under treatment

Variation in visual analogic scale (VAS) value

Time frame: Each visit (Baseline,Week 16, Week 28, Week 52)

Evaluation of quality of life under treatement

Dermatology Life Quality Index (DLQI) score compared to Baseline Visit

Time frame: Each visit (Baseline, Week16, Week 28, Week 52)

Evaluation of satisfaction under treatement